Global Therapeutic Landscape for Chemotherapy Induced Peripheral Neuropathy, H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 6, 20 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape for Chemotherapy Induced Peripheral Neuropathy.
  • The pipeline guide reviews pipeline therapeutics by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Chemotherapy Induced Peripheral Neuropathy - Overview
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
  • Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
  • Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
  • Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Companies Mentioned

  • Achelios Therapeutics Inc
  • Apexian Pharmaceuticals Inc
  • Aphios Corp
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Bristol-Myers Squibb Co
  • Candel Therapeutics
  • Disarm Therapeutics Inc
  • Emerald Bioscience Inc
  • Exodos Life Sciences Limited Partnership
  • Immune Pharmaceuticals Inc
  • KannaLife Sciences Inc
  • Kineta Inc
  • Kyorin Pharmaceutical Co Ltd
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Mundipharma International Ltd
  • NeurExo Sciences LLC
  • Osmol Therapeutucs Inc
  • PharmatrophiX Inc
  • PledPharma AB
  • Regulonix LLC
  • Sensei Biotherapeutics Inc
  • SiteOne Therapeutics Inc
  • Sonnet BioTherapeutics Inc
  • Sova Pharmaceuticals Inc
  • Stealth BioTherapeutics Corp
  • Toray Industries Inc
  • Trevena Inc
  • WEX Pharmaceuticals Inc
  • Winsantor Inc
  • YD Life Science Co

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sjwbqq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900